Показати скорочений опис матеріалу
dc.contributor.author | Yakymenko, O. O. | en |
dc.contributor.author | Savytskyi, V. I. | en |
dc.contributor.author | Klochko, V. V. | en |
dc.contributor.author | Savytskyi, I. V. | en |
dc.contributor.author | Badiuk, N. S. | en |
dc.date.accessioned | 2022-02-18T13:21:31Z | |
dc.date.available | 2022-02-18T13:21:31Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Changes in vasoconstructor-vasodilation potential of vessels in experimental antiphospholipid syndrome / O. O. Yakymenko, V. I. Savytskyi, V. V. Klochko et al // Pharmacology Online. 2021. Vol. 2. P. 819–826. | en |
dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/11237 | |
dc.description.abstract | As a result of our study, the development of endothelial dysfunction in experimental antiphospholipid syndrome is confirmed: an increase in the marker of ED (endothelin-1) and a pathological increase in vasoconstrictor potential on the background of weakening of vasodilatation. There was a pathological increase in the vasoconstrictor potential of blood vessels in animals simulated antiphospholipid syndrome, as evidenced by an increase in endothelin-1 levels in the blood of rats (p <0,001). Violation of nitric oxide synthesis was detected against the background of the development of experimental antiphospholipid syndrome, which is confirmed by a marked decrease in the level of Snitrosothiols. The most pronounced normalization of vasoconstrictor-vasodilatory potential of vessels was found in rats, whose simulated antiphospholipid syndrome was corrected with warfarin, immunoglobulin and L-arginine solution. | en |
dc.language.iso | en | en |
dc.subject | antiphospholipid syndrome | en |
dc.subject | L-arginine | en |
dc.subject | endothelin-1 | en |
dc.subject | S-nitrosothiols | en |
dc.subject | immunoglobulin | en |
dc.subject | warfarin | en |
dc.title | Changes in vasoconstructor-vasodilation potential of vessels in experimental antiphospholipid syndrome | en |
dc.type | Article | en |